ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO688

Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Prespecified Analysis of the ASCEND-D Trial

Session Information

  • Anemia and Iron Metabolism
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Dasgupta, Indranil, University Hospitals of Birmingham NHS Foundation Trust, Birmingham, United Kingdom
  • Mallett, Stephen, GSK, Brentford, United Kingdom
  • Bhatt, Purav Rahulkumar, GSK, Collegeville, Pennsylvania, United States
  • Acharya, Anjali, Albert Einstein College of Medicine, Bronx, New York, United States
  • Aarup, Michael, Odense University Hospital, Odense, Denmark
  • Correa-Rotter, Ricardo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
  • Gupta, Shruti, Brigham and Women’s Hospital, Boston, Massachusetts, United States
  • Kher, Vijay K., Medanta Kidney and Urology Institute, Medanta Hospital, South Delhi, India
  • Vieira Neto, Osvaldo Merege, Sociedade Brasileira de Nefrologia, São Paulo, Brazil
  • Rastogi, Anjay, David Geffen School of Medicine UCLA, Los Angeles, California, United States
  • Ots-Rosenberg, Mai, Tartu University Hospital, Tartu, Estonia
  • Rayner, Brian, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa
  • Wong, Muh Geot, University of Sydney, Sydney, New South Wales, Australia
  • Singh, Ajay K., Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States

Daprodustat (Dapro), an oral investigational hypoxia-inducible factor prolyl hydroxylase inhibitor, has been shown to be noninferior to conventional erythropoietin stimulating agents in renal anemia treatment of dialysis and non-dialysis patients (pts). This pre-specified subgroup analysis of the ASCEND-D trial examined the efficacy and cardiovascular (CV) safety of Dapro vs darbepoetin-alfa (Darbe) in end-stage kidney disease (ESKD) pts receiving peritoneal dialysis (PD).


ASCEND-D (NCT02879305) was an open-label, phase 3 trial in ESKD pts on dialysis with screening hemoglobin (Hb) 8.0–11.5g/dL, randomized to Dapro or Darbe. Primary outcomes were mean Hb change from baseline to wks 28 through 52 (noninferiority [NI] margin -0.75g/dL) and first occurrence of a major adverse CV event (MACE: a composite of death from any cause, nonfatal myocardial infarction [MI], or nonfatal stroke [NI margin 1.25]). Mean Hb change was analyzed via an analysis of covariance model adjusting for baseline Hb, treatment, dialysis modality, and geographic region. MACE was analyzed via a Cox proportional-hazards model adjusting for treatment, dialysis modality, and geographic region.


Overall, 340 PD pts (Dapro n=171; Darbe n=169) were randomized (baseline [Dapro/Darbe]: mean age, years [54/53]; % male [56/54]; % dialysis vintage >5 years [18/22]; Hb, g/dL [10.25/10.23]; % stroke [5/5]; and % MI [8/7]). For Dapro and Darbe respectively, the mean change in Hb was 0.38 and 0.23g/dL (adjusted mean difference 0.15 95% confidence interval [CI] -0.04–0.34); a first occurrence of adjudicated MACE occurred in 40 (23.4%) and 46 (27.2%) pts (hazard ratio 0.84 95% CI 0.55–1.28) and the mean average monthly iron dose was 59.6g and 62.9g (adjusted mean difference -3.3 95% CI -30.7–24.0). There was no heterogeneity between PD and hemodialysis pts for these endpoints. Peritonitis rates were 26% (Dapro) and 22% (Darbe).


This pre-specified sub-group analysis of the ASCEND-D trial demonstrates comparable efficacy and CV safety of Dapro vs Darbe in PD pts, supporting use of this novel oral agent in anemic PD pts.


  • Commercial Support –